Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968846 · ClinicalTrials.gov registry record · Phase 2
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
A Phase 2 study, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT05968846 is a Phase 2 study that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 19 participants.
The verdict
NCT05968846, a Phase 2 study, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of organ-specific amyloid load.
Interventions
- DRUG Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968846
The ClinicalTrials.gov registry entry for NCT05968846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee Graduate School of Medicine, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01) is the first listed.
NCT05968846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05968846 about?
NCT05968846 is a clinical study titled "Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load". The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of org...
What is the current status of trial NCT05968846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-12-07. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05968846?
The interventions under investigation include: Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01) (DRUG).
Who is sponsoring clinical trial NCT05968846?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.